Is There Evidence of Any Safety Differences Among DPP-4 Inhibitors in the Treatment of People with Type 2 Diabetes Mellitus and Reduced GFR Due to Chronic Kidney Disease?

about

Hypoglycemic Coma in a Hemodialysis Patient Receiving Blood Glucose-Lowering Therapy With the Single Agent Teneligliptin.

P2860

Q55002223-ED20EE15-363C-4B3B-A8BC-D5B0F05EA39B

P2860

Is There Evidence of Any Safety Differences Among DPP-4 Inhibitors in the Treatment of People with Type 2 Diabetes Mellitus and Reduced GFR Due to Chronic Kidney Disease?

Item

http://www.wikidata.org/entity/Q41856389

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Is There Evidence of Any Safet ...... Due to Chronic Kidney Disease?

@en

type

Item

label

Is There Evidence of Any Safet ...... Due to Chronic Kidney Disease?

@en

prefLabel

Is There Evidence of Any Safet ...... Due to Chronic Kidney Disease?

@en

P1476

Is There Evidence of Any Safet ...... Due to Chronic Kidney Disease?

@en

P2093

Anja Schweizer

http://www.w3.org/2001/XMLSchema#string

James E Foley

http://www.w3.org/2001/XMLSchema#string

Marc Evans

http://www.w3.org/2001/XMLSchema#string

Sylvie Dejager

http://www.w3.org/2001/XMLSchema#string

P2860

Long-term efficacy and safety of linagliptin in patients with type 2 diabetes and severe renal impairment: a 1-year, randomized, double-blind, placebo-controlled study

Drug use evaluation of sitagliptin dosing by pharmacist versus nonpharmacist clinicians in an internal medicine department of a private physician-owned multispecialty clinic.

Drug use and dosing in chronic kidney disease.

Antidiabetic agents in patients with chronic kidney disease and end-stage renal disease on dialysis: metabolism and clinical practice.

Incretin therapies in the management of patients with type 2 diabetes mellitus and renal impairment.

Linagliptin: a review of its use in the management of type 2 diabetes mellitus.

Clinical evidence and mechanistic basis for vildagliptin's effect in combination with insulin.

Metformin and other antidiabetic agents in renal failure patients.

Pharmacokinetics and clinical use of incretin-based therapies in patients with chronic kidney disease and type 2 diabetes.

KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 Update.

P2888

s13300-015-0104-4

P304

1-5

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

editorial

P356

10.1007/S13300-015-0104-4

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-03-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

273785638

http://www.w3.org/2001/XMLSchema#string

P698

25783754

http://www.w3.org/2001/XMLSchema#string

P921

type-2 diabetes

P932

4374076

http://www.w3.org/2001/XMLSchema#string

Is There Evidence of Any Safety Differences Among DPP-4 Inhibitors in the Treatment of People with Type 2 Diabetes Mellitus and Reduced GFR Due to Chronic Kidney Disease?

about

P2860

P2860

Is There Evidence of Any Safety Differences Among DPP-4 Inhibitors in the Treatment of People with Type 2 Diabetes Mellitus and Reduced GFR Due to Chronic Kidney Disease?

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P5875

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P5875

P698

P921

P932